Trials / Withdrawn
WithdrawnNCT05983146
Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies
A Phase I, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-7053 Injection in Patients With Advanced Malignancies
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of multiple administration of HRS-7053 in patients with advanced malignancies Determine the maximum tolerated dose (MTD, if possible) and the recommended dose for Phase II clinical studies (RP2D)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-7053 Injection | HRS-7053 is administered by intravenous (IV) infusion once a week (QW) for one treatment cycle every 4 weeks |
Timeline
- Start date
- 2023-09-01
- Primary completion
- 2025-05-30
- Completion
- 2025-05-30
- First posted
- 2023-08-09
- Last updated
- 2025-07-24
Source: ClinicalTrials.gov record NCT05983146. Inclusion in this directory is not an endorsement.